Drug Development
University of Sydney Researchers Discover Potential Breakthrough in Parkinson's Treatment
A preclinical study by University of Sydney researchers has successfully reversed Parkinson's-like symptoms in mice by targeting a malfunctioning protein, offering hope for future human treatments.
Silo Pharma Inc. Anticipates Key Study Results for PTSD Treatment SPC-15
Silo Pharma Inc. is on the verge of receiving crucial preclinical study results for SPC-15, a potential breakthrough in PTSD treatment, marking a significant step towards addressing a long-unmet medical need.
Oragenics Inc. Raises $16.5 Million to Advance Intranasal Concussion Therapy
Oragenics Inc. has successfully closed a $16.5 million public offering to fund the development of its intranasal therapy for concussions, marking a significant step forward in neurological disorder treatments.
Nutriband Inc. Advances in Opioid Safety with AVERSA(TM) Fentanyl Milestone
Nutriband Inc. achieves a significant milestone in the development of AVERSA(TM) Fentanyl, an abuse-deterrent opioid, marking progress in addressing the global opioid crisis.
GeoVax Announces $6 Million Public Offering to Advance Immunotherapies and Vaccines
GeoVax Labs, Inc. secures approximately $6 million in a public offering to fund the development of its immunotherapies and vaccines against cancer and infectious diseases.
Soligenix Inc. Advances Novel Immunotherapy to Combat Antibiotic Resistance
Soligenix Inc. is developing SGX943, a novel immunotherapy that enhances the body's immune response to combat bacterial infections, addressing the critical challenge of antibiotic resistance.
Lantern Pharma's AI Platform Shows Promise in Lung Cancer Treatment
Lantern Pharma's AI-driven drug development platform, RADR®, has demonstrated significant potential in treating non-small cell lung cancer, with a Phase 2 trial patient achieving a complete response after previous treatments failed.
NeuroSense Therapeutics Advances Toward Canadian Fast-Track Approval for ALS Drug PrimeC
NeuroSense Therapeutics' progress with Health Canada for its ALS drug PrimeC could accelerate approval and bolster a significant pharmaceutical partnership, highlighting a pivotal moment for ALS treatment and the biotech sector.
CNS Pharmaceuticals Inc. Sheds Light on GBM Treatment Advances in KOL Segment
CNS Pharmaceuticals Inc. (NASDAQ: CNSP) explores the potential of its lead product candidate, TPI 287, in treating Glioblastoma Multiforme (GBM) and future metastatic tumor indications, as discussed by Dr. Erin Dunbar in a recent Virtual Investor KOL Connect segment.
Creative Biolabs Advances mRNA Therapeutics with Comprehensive Solutions
Creative Biolabs is enhancing the development of mRNA therapies, offering innovative solutions that address key challenges in stability, delivery, and scalability, pivotal for treatments ranging from HIV to cancer.
Nutriband Inc. (NASDAQ: NTRB) Sees Price Target Increase to $15 After AVERSA Fentanyl Manufacturing Achievement
Nutriband Inc.'s price target was raised to $15 following the successful commercial manufacturing and scale-up of its AVERSA Fentanyl abuse-deterrent transdermal patch, marking a significant step towards clinical trials and potential market entry.
NanoViricides' NV-387 Emerges as a Promising Broad-Spectrum Antiviral Against COVID-19 and Bird Flu
NanoViricides, Inc. highlights NV-387, its broad-spectrum antiviral candidate, as a potential game-changer in combating emerging COVID-19 variants and Bird Flu strains, showcasing its superior performance in animal models and readiness for cGMP manufacturing.
Lantern Pharma Inc. Reports Complete Response in Advanced NSCLC Patient in HARMONIC(TM) Trial
Lantern Pharma Inc. (NASDAQ: LTRN) has reported a significant clinical outcome in its Phase 2 HARMONIC(TM) trial, showcasing the potential of its LP-300 treatment in combination with standard chemotherapy for never-smoker patients with advanced non-small cell lung cancer (NSCLC), marking a pivotal moment in oncology treatment.
Nutriband Inc. Reports Significant Revenue Growth and Advances in AVERSA Fentanyl Development
Nutriband Inc. showcases a 63% year-over-year revenue increase in Q1 2025 and progresses in developing AVERSA Fentanyl, aiming to introduce the first abuse-deterrent opioid patch globally.
Lifordi Immunotherapeutics Unveils Promising Preclinical Data for LFD-200 at EULAR 2025
Lifordi Immunotherapeutics has presented preclinical data on LFD-200, a novel antibody-drug conjugate targeting autoimmune and inflammatory diseases, showing efficacy without systemic toxicity, marking a potential breakthrough in treatment options.
Creative Biolabs Advances Microbiome-Based Drug Development with Enhanced LBP Analytics
Creative Biolabs has introduced an advanced microbial service platform to streamline the development of microbiome-based drugs, addressing key challenges in strain characterization, contaminant detection, and formulation stability.
Alfa Cytology Launches PARP Inhibitors Development Services for Advanced Cancer Treatment
Alfa Cytology has introduced comprehensive development services for PARP inhibitors, offering a promising avenue for more precise and personalized cancer treatments, particularly for cancers with genetic mutations like BRCA1 and BRCA2.
FDA's Accelerated Launch of AI Tool Elsa Sparks Transparency and Oversight Concerns
The FDA's early release of its AI tool, Elsa, aims to enhance efficiency in drug development processes but has ignited debates over the lack of transparency and potential oversight issues.
Calidi Biotherapeutics Unveils Promising Data on CLD-401 at ASCO 2025
Calidi Biotherapeutics Inc. presents groundbreaking data on its lead candidate CLD-401 at the ASCO Annual Meeting, showcasing advancements in systemic oncolytic targeted immunotherapies with potential implications for cancer treatment.
NanoViricides Advances Measles Drug Program as Global Outbreaks Rise
NanoViricides, Inc. has begun animal trials for its antiviral candidate NV-387, targeting measles amidst increasing global outbreaks and vaccine challenges, highlighting a critical step towards addressing a significant public health gap.
Soligenix Inc. (SNGX) Reports Promising HyBryte Results for CTCL Treatment
Interim data from a Soligenix Inc. study highlights HyBryte's potential as a safer, faster-acting treatment for cutaneous T-cell lymphoma, offering new hope for patients with this chronic condition.
Telomir Pharmaceuticals Advances Telomere-Targeting Drug, Seeks Strategic Partnerships
Telomir Pharmaceuticals is preparing to submit an Investigational New Drug (IND) application for Telomir-1, a potential breakthrough small molecule targeting aging mechanisms, with plans to explore strategic collaborations at the BIO International Convention 2025.
Nutriband Reports Record Q1 Revenue, Advances Abuse-Deterrent Fentanyl Patch Development
Nutriband Inc. reported a 63% year-over-year revenue increase in Q1, driven by expanded kinesiology tape production and retail presence, while simultaneously progressing its AVERSA Fentanyl patch development through a strategic partnership with Kindeva Drug Delivery.
Alzamend Neuro Advances Innovative Therapies for Mental Health Disorders
Alzamend Neuro is developing novel therapeutic approaches for challenging neurological and psychiatric conditions, including Alzheimer's, Bipolar Disorder, Major Depressive Disorder, and PTSD. The company's pioneering treatments aim to improve patient outcomes by addressing current treatment limitations.
Alzamend Neuro Launches Phase II Trial for Innovative Lithium-Based Alzheimer's Therapy
Alzamend Neuro has initiated a Phase II clinical trial for AL001, a novel lithium therapy targeting multiple neuropsychiatric conditions, with potential to improve brain drug delivery and reduce side effects.
RNA Pioneer Dr. Phillip Zamore Joins TransCode Therapeutics' Scientific Advisory Board
TransCode Therapeutics has appointed Dr. Phillip D. Zamore, a leading RNAi researcher, to its Scientific Advisory Board, potentially strengthening the company's oncology research capabilities and RNA therapeutic development strategies.
RNAi Pioneer Dr. Phillip Zamore Joins TransCode Therapeutics' Scientific Advisory Board
TransCode Therapeutics strengthens its scientific leadership by appointing renowned RNA interference expert Dr. Phillip Zamore to its Scientific Advisory Board, potentially boosting the company's cancer therapeutic research capabilities.
Creative Biolabs Expands CAR-T Therapy Development with Comprehensive CDMO Services
Creative Biolabs is offering end-to-end solutions for CAR-T therapy development, providing comprehensive services from plasmid design to viral vector manufacturing, potentially accelerating personalized cancer treatment research.
NanoViricides Highlights Potential Antiviral Solution Amid Changing COVID Booster Recommendations
NanoViricides' President Dr. Anil Diwan comments on the FDA's updated COVID-19 booster policy, emphasizing the need for alternative antiviral treatments and positioning the company's NV-387 drug candidate as a potential solution for respiratory viral infections.
Quantum BioPharma Advances Multiple Sclerosis Drug Toward Clinical Trials
Quantum BioPharma has signed an agreement with a contract research organization to prepare an Investigational New Drug application for Lucid-21-302, a potential breakthrough therapy for multiple sclerosis that could prevent neurological damage.